CardioGenics Holdings Inc. (CGNH)

[02opida]

CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care? analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it, and its newly created Canadian subsidiary, have entered into a definitive asset purchase agreement to acquire substantially all of the assets of Plasticap. CardioGenics previously announced on October 5, 2015 that it had entered into a binding letter of intent to acquire substantially all of Plasticap's assets.